0
Pulmatrix, Inc. Banner Image

Pulmatrix, Inc.

  • Ticker PULM
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Pulmatrix, Inc. Logo Image
  • 11-50 Employees
  • Based in Lexington, Massachusetts
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSEā„¢ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonaryMore aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSEā„¢, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
Pulmatrix, Inc.

Most Recent Annual Report

Pulmatrix, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Pulmatrix, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!